ライフサイエンスコーパス: ventilatory support

1 ssfully extubated without needing additional ventilatory support.

2 ed from normotensive donors after 6 hours of ventilatory support.

3 ergoing tracheostomy and receiving prolonged ventilatory support.

4 atients were monitored during 64 episodes of ventilatory support.

5 ure infants who require prolonged periods of ventilatory support.

6 , broad-spectrum antibiotics, and mechanical ventilatory support.

7 us that can assist with decisions to provide ventilatory support.

8 expiratory muscle pacing to provide complete ventilatory support.

9 ustained a WOBTot of 0.6 to 1 J/L during the ventilatory support.

10 maintaining diaphragm activity under partial ventilatory support.

11 Fifteen (13.2%) required ventilatory support.

12 D was defined by need for intensive care and ventilatory support.

13 shortness of breath (55%), and 11% required ventilatory support.

14 red supplemental oxygen and 68 (2.6%) needed ventilatory support.

15 ) mutation, with patients requiring lifelong ventilatory support.

16 e (COVID-19) require supplemental oxygen and ventilatory support.

17 m cardiopulmonary resuscitation to long-term ventilatory support.

18 patients before and after the withdrawal of ventilatory support.

19 minor respiratory interventions, and use of ventilatory support.

20 eflexic quadriplegia and required mechanical ventilatory support.

21 creasing the risk for failed liberation from ventilatory support.

22 blood products, fluid balance, and modes of ventilatory support.

23 c, may alleviate the anxiety associated with ventilatory support.

24 spiratory failure to insure need for ongoing ventilatory support.

25 ostomy to patients with a need for continued ventilatory support.

26 of spasm control that can avoid the need for ventilatory support.

27 nsion, cautious diuresis, and, if necessary, ventilatory support.

28 volume and gas exchange while requiring less ventilatory support.

29 eased level of consciousness often requiring ventilatory support.

30 ut might be advantageous because it provides ventilatory support.

31 childhood, but survived to adulthood without ventilatory support.

32 h-75th percentile) of 9.0 (5.0-14.0) days of ventilatory support.

33 gan dysfunction, and need for vasopressor or ventilatory support.

34 unit hospitalization, or days on mechanical ventilatory support.

35 nsplant and subsequently required mechanical ventilatory support.

36 intensive care unit who required mechanical ventilatory support.

37 mortality and often necessitating mechanical ventilatory support.

38 l responses to sternal closure or changes in ventilatory support.

39 EPA+GLA required significantly fewer days of ventilatory support (11 vs. 16.3 days; p = .011), and ha

40 The preset proportion of ventilatory support (30%, 50%, and 70%) unloaded the wor

41 (age, 59 +/- 17 yrs; duration of mechanical ventilatory support, 45 +/- 36 days [mean +/- sd]) agree

42 right-heart catheterisation (57 vs 22%); and ventilatory support (54 vs 38%).

43 OVID-19 (4.58%), and 336 required mechanical-ventilatory support (.58%).

44 gnificantly more likely to require prolonged ventilatory support (66.7% vs 21.4%), undergo dialysis (

45 % CI, 0.05-1.44; P = .04), longer mechanical ventilatory support (9.44 [15.27] vs 3.78 [8.42] days; d

46 ithholding cardiopulmonary resuscitation and ventilatory support after day 3 of coma.

47 ry failure, requiring supplemental oxygen or ventilatory support and elevated thrombo-inflammatory ma

48 f > or =34 wks who were receiving mechanical ventilatory support and had echocardiographic and clinic

49 jective measurement to guide the adequacy of ventilatory support and interpret apparent clinical wean

50 ge in oxygenation and duration of mechanical ventilatory support and supplemental oxygen therapy.

51 extubation, despite the need for continuous ventilatory support and, thereby, decrease the need to r

52 with severe COVID-19 who required mechanical ventilatory support and/or intensive care unit admission

53 therapeutic-dose cohort required noninvasive ventilatory support, and 6 patients (60%) did not requir

54 l-cause death, respiratory failure requiring ventilatory support, and hospitalization duration.

55 Organ Failure Assessment score, duration of ventilatory support, and mortality.

56 n supplementation, nasogastric-tube feeding, ventilatory support, and relative improvement in the cli

57 organ failure, required prolonged mechanical ventilatory support, and resulted in a high workload for

58 ith high rates of pneumonia, requirement for ventilatory support, and short- and long-term mortality.

59 Two patients were discharged with nocturnal ventilatory support, and the rest were completely weaned

60 sive care unit, number of days on mechanical ventilatory support, and time to death.

61 us TGI at two levels of decreased mechanical ventilatory support; and (2) determine an appropriate ti

62 iring hospital admission, 48 (32%) requiring ventilatory support] and troponin elevation discharged f

63 ry rehabilitation, self-management, and home ventilatory support are becoming increasingly important,

64 o had advanced respiratory failure requiring ventilatory support at the time of oseltamivir initiatio

65 hors attempted to re-engineer the process of ventilatory support based on measured work of breathing

66 ostomy should be made on day 8 of mechanical ventilatory support because of the low probability of su

67 rials resulted in liberation from mechanical ventilatory support before another spontaneous breathing

68 he rest were completely weaned of mechanical ventilatory support before discharge.

69 Clinically relevant decrease in ventilatory support before WLST = 11% ( n = 100), and 17

70 Decreasing ventilatory support before WLST with extubation in child

71 ( n = 161) had likely incidental decrease in ventilatory support before WLST.

72 birth weight of 1250 g or less who required ventilatory support between 7 and 21 days of age.

73 Ventilatory support, blood-pressure reduction, intracran

74 he TCS tool, increased the risk of requiring ventilatory support by 4-fold.

75 ble clinical accuracy for patients receiving ventilatory support by using an ANN.

76 We analyzed trends in the use of ventilatory support, corticosteroid therapy, antibiotic

77 Pneumonia rates per 1000 ventilatory support days were 20:1000 in the HHME-24 gro

78 compare characteristics of patients who had ventilatory support decreased before WLST with those who

79 he time of moderate/severe ARDS diagnosis to ventilatory support discontinuation within 7-days, 28-da

80 e unit admission, intubation, and mechanical ventilatory support due to acute traumatic brain injury

81 yr of age) were disconnected from mechanical ventilatory support during Stage III-IV NREM, and their

82 ed through an oral endotracheal tube (off of ventilatory support) during 1 min of spontaneous respira

83 tress syndrome with the need for noninvasive ventilatory support either as initial treatment after bi

84 those had a severe clinical course (invasive ventilatory support, extracorporeal membrane oxygenation

85 For patients requiring ventilatory support for > or = 20 days, 100% of patients

86 riterion is likely to prolong intubation and ventilatory support for a large number of patients.

87 ne for hypotension, and one patient required ventilatory support for hypoxia.

88 ICU and were expected to continue to receive ventilatory support for longer than the next calendar da

89 Adult patients with ventilatory support for more than 60 days.

90 of ACS, leading to endotracheal intubation, ventilatory support for respiratory failure, and erythro

91 Among ICU patients receiving acute ventilatory support for respiratory failure, PDM resulte

92 mmendations about withholding or withdrawing ventilatory support for respiratory failure.

93 ht (OR, 3.41; 95% CI, 1.61-7.26), and use of ventilatory support for the newborn (OR, 2.85; 95% CI, 1

94 Ventilatory support for the patient was successfully man

95 s less than 3 months old who did not require ventilatory support for whom brain MRI was indicated.

96 ions of domiciliary medical technology, home ventilatory support has either led or run in parallel wi

97 after extubation and timely reinstitution of ventilatory support has the potential to reduce the incr

98 atment intensity varied with vasopressor and ventilatory support in 69.0% and 83.0% of patients in Am

99 TE without decrease in ventilatory support in the 6 hours prior = 71.4% ( n = 6

100 71.4% ( n = 652) had TE without decrease in ventilatory support in the 6 hours prior.

101 AV-ECMO may provide efficient ventilatory support in the neonatal population with hype

102 % of infants vs. 48.7%, P=0.04), less use of ventilatory support (in 4.0% vs. 10.8%, P=0.01), and few

103 tions, group B RSV infection rarely required ventilatory support, in contrast to group A infections (

104 maternal benzodiazepine treatment, rates of ventilatory support increased by 61 of 1000 neonates and

105 asive hemodynamic monitoring, and aggressive ventilatory support, inhaled nitric oxide was administer

106 mes included in-hospital mortality, need for ventilatory support, intensive care unit (ICU) admission

107 ome measures assessed included inotropic and ventilatory support, intensive care, and hospital stay.

108 theterisation, intravenous inotropic agents, ventilatory support, intra-aortic balloon counterpulsati

109 rms of mechanical support include mechanical ventilatory support, intraaortic balloon counterpulsatio

110 in lower income countries included advanced ventilatory support, invasive and noninvasive monitoring

111 Ventilatory support is an essential life-saving tool for

112 Ventilatory support is appropriate for some transplant c

113 Prolonged ventilatory support is common, and good functional outco

114 spiratory distress should be considered when ventilatory support is not readily available.

115 iated with mortality included precannulation ventilatory support longer than 2 wks and lower precannu

116 The outcome of ICU admission or need for ventilatory support may not capture all severe COVID-19

117 atients) or 3 days (reintubated patients) of ventilatory support met tracheostomy criteria.

118 sed long before enteral feeding or assistive ventilatory support might be considered.

119 HR, 1.08 [CI, 0.58 to 2.02]) or the need for ventilatory support (molnupiravir: HR, 1.07 [CI, 0.89 to

120 ong the 227 patients who required mechanical ventilatory support, mortality was significantly lower i

121 , intermediate severity requiring mechanical ventilatory support (MVS), and critical severity requiri

122 uring Lunit INSIGHT CXR, TCS) to predict the ventilatory support need based on pneumonic progression

123 associated with an increase in intensity of ventilatory support, NIV failure, and intensive care uni

124 tory severity groups: no need for mechanical ventilatory support (No-MVS), intermediate severity requ

125 Nonstandard ventilatory support of patients with CDH has led to sign

126 ffect of prone positioning during mechanical ventilatory support on outcomes.

127 ed to continuous use of noninvasive IPPV for ventilatory support on room air.

128 se patients received invasive or noninvasive ventilatory support on their first ICU day versus 65% wi

129 been discharged from the hospital, need for ventilatory support or an intracranial catheter, and a P

130 Receipt of inotropic or ventilatory support or death occurred in 56 patients who

131 approaches for predicting either increasing ventilatory support or mortality.

132 has no substantial impact on the duration of ventilatory support or mortality.

133 dexamethasone or placebo with either routine ventilatory support or permissive hypercapnia.

134 2.06; 95% CI, 1.87-2.27; p<.0001), prolonged ventilatory support (OR, 1.79; 95% CI, 1.72-1.86; p<.000

135 ourse (death, discharge to hospice, invasive ventilatory support, or extracorporeal membrane oxygenat

136 zes the trends and growing evidence base for ventilatory support outside the hospital.

137 m 19 were successfully weaned off mechanical ventilatory support over a mean period of 3.7+/-4.0 days

138 One of the great advances in ventilatory support over the past few decades has been t

139 viously hospitalized due to severe COVID-19 (ventilatory support, oxygen flow >=5 L/min, or both) wit

140 compared with 2.5% in patients not requiring ventilatory support (P < .01).

141 Ventilatory support parameters and systemic PaO2/FiO2 ra

142 Outcome measures included ventilatory support parameters, arterial blood gases, or

143 =.046), but not with duration of mechanical ventilatory support (r = -.23) or VRU admission Acute Ph

144 Length of mechanical ventilatory support ranged from 1 to 112 days, mean 14.8

145 and 36% of the patients required mechanical ventilatory support, ranging in duration from 1 to 70 da

146 s with unplanned extubation occurring during ventilatory support required reintubation.

147 h COVID-19 pneumonia allows us to anticipate ventilatory support requirements requiring less than hal

148 preextubation measures of breathing effort, ventilatory support, respiratory mechanics, central insp

149 urs), broad-spectrum antibiotic therapy, and ventilatory support resulted in full recovery without th

150 If patients failed due to hypoxia, ventilatory support resumed.

151 c therapist whenever desired while receiving ventilatory support, self-initiated use of noise-canceli

152 mised after delayed sternal closure and that ventilatory support should be increased to counteract th

153 wise, the minute volume of positive pressure ventilatory support should be limited with potential sev

154 t such effect may provide future noninvasive ventilatory support strategies in patients with CCHS and

155 umonia may put patients at risk of requiring ventilatory support, such as non-invasive mechanical ven

156 resent at various times during the period of ventilatory support, supporting a role for mediator-indu

157 ciated with a shorter duration of mechanical ventilatory support than was early parenteral nutrition

158 underlying disease, rather than duration of ventilatory support, that have a significant impact on Q

159 e care unit admission, the need for invasive ventilatory support, the length of hospital stay, or the

160 cipients who subsequently require mechanical ventilatory support, there appear to be some groups with

161 After removing 24 cases only treated with ventilatory support, there were 1343 OA-OHCAs and 9556 u

162 Titrating ventilatory support to maintain normal levels of inspira

163 if they met eligibility criteria for partial ventilatory support, tolerated pressure support ventilat

164 ay in small infants unable to be weaned from ventilatory support, tracheobronchography may be a more

165 nd with an increased frequency of oxygen and ventilatory support use.

166 evious myocardial infarction, renal disease, ventilatory support, use of circulatory support, glycopr

167 , comorbidities, hemodynamic parameters, and ventilatory support used before ECLS.

168 In survivors of prolonged mechanical ventilatory support, using specific selection criteria s

169 Ventilatory support variables, airway care, device costs

170 compared with 7.0 [0.0-17.6] d; P < 0.001), ventilatory support (ventilator-free days to day 28: 16.

171 The mean duration of ventilatory support was 10 days (range, 9-11); the mean

172 st RSV-associated bronchiolitis resulting in ventilatory support was 67.2% (95% CI, 38.6 to 82.5) (27

173 Change in ventilatory support was assessed and three clusters of c

174 Nitric oxide was discontinued when ventilatory support was decreased to a PEEP of < or = 6

175 to predict which patients required extended ventilatory support was limited.

176 Ventilatory support was measured by the fraction of insp

177 t reduction in ICU admission or the need for ventilatory support was observed.

178 oxygen therapy, nasogastric-tube feeding, or ventilatory support was recorded.

179 Prolonged mechanical ventilatory support was the most common indication.

180 NGE, 514 adult patients receiving mechanical ventilatory support were admitted to the intensive care

181 and March 31, 2020, who required mechanical ventilatory support were included.

182 h confirmed H1N1 pneumonia and on mechanical ventilatory support were randomized to receive adjuvant

183 Arterial blood gases and level of ventilatory support were recorded before and at 6, 24, 4

184 Supplemental oxygen and ventilatory support were required in 67.9% and 11.1%, re

185 ency requiring airway support or oxygenation/ventilatory support were treated with bilevel positive a

186 tment could not be blinded, vasopressors and ventilatory support were weaned by protocol.

187 isk-criteria donor had greater pretransplant ventilatory support, whereas adult recipients of a PHS r

188 Higher PCO2 levels may allow a reduction in ventilatory support which reduces the risk of lung injur

189 and 6 patients (60%) did not require regular ventilatory support, which did not change in long-term f

190 This condition necessitates ventilatory support, which when prolonged leads to acute

191 s lung-protective ventilation during partial ventilatory support, while maintaining diaphragm activit

192 Survivors of prolonged mechanical ventilatory support who were discharged from a ventilato

193 oxygen (Pao2) decreases to 40 mm Hg, despite ventilatory support with a fraction of inspired oxygen (

194 st 24 hours and were able to undergo partial ventilatory support with PSV but were not yet ready for

195 tensive care unit (ICU) admission, or use of ventilatory support within 28 days.

196 respiratory flutter and permitted weaning of ventilatory support within a few hours.

197 days alive and breathing without mechanical ventilatory support within the first 28 days after rando